Simple Strategies for Vaginal Health Promotion in Cancer Survivors

Journal of Sexual Medicine

Volumn 8, Issue 2, 2011, Pages 549-559

  Carter, Jeanne ^a   Goldfrank, Deborah ^a   Schover, Leslie R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Estrogen deprivation symptoms in cancer survivors; Sex; Survivorship; Vaginal health

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; GESTAGEN; HYALURONIC ACID; LUBRICATING AGENT; POLYCARBOPHIL; PRASTERONE; RALOXIFENE; RETINOL; SILICONE; TAMOXIFEN; WATER;

ALGORITHM; ARTICLE; AWARENESS; BREAST CANCER; CANCER SURVIVOR; DEVICE; DYSPAREUNIA; EVIDENCE BASED MEDICINE; FEMALE SEXUAL DYSFUNCTION; HEALTH PROMOTION; HUMAN; MORBIDITY; OVARY CANCER; PATIENT CARE; PATIENT EDUCATION; PELVIC FLOOR MUSCLE TRAINING; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VAGINA ATROPHY; VAGINA PAIN; VAGINAL BURNING SENSATION; VAGINAL DILATOR; VAGINAL DRYNESS; VAGINAL HEALTH PROMOTION; VAGINAL PRURITUS; VAGINITIS;

EID: 79551471176     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01988.x     Document Type: Article

References (87)

1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
2. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94.
3. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-9.
4. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519-30.
5. Gupta P, Sturdee DW, Palin SL, Majumder K, Fear R, Marshall T, Paterson I. Menopausal symptoms in women treated for breast cancer: The prevalence, and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49-58.
6. Schover LR. Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008;26:753-8.
7. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
8. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15(4 Pt 1):661-6.
9. Avis NE, Brockwell S, Randolph JF Jr, Shen S, Cain VS, Ory M, Greendale GA. Longitudinal changes in sexual functioning as women transition through menopause: Results from the Study of Women's Health Across the Nation. Menopause 2009;16:442-52.
10. Schover LR. Counseling cancer patients about changes in sexual function. Oncology (Williston Park) 1999;13:1585-91.discussion 1591-1592, 1595-1596.
11. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. N Engl J Med 1999;340:1383-9.
12. Saibishkumar EP, Patel FD, Sharma SC. Evaluation of late toxicities of patients with carcinoma of the cervix treated with radical radiotherapy: An audit from India. Clin Oncol (R Coll Radiol) 2006;18:30-7.
13. Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008;71:1335-42.
14. Flay ID, Matthews J. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. Int J Radiat Oncol Biol Phys 1995;31:399-404.
15. Bruner DW, Lanciano R, Keegan M, Corn B, Martin E, Hanks GE. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993;27:825-30.
16. Robinson JW. Sexuality and cancer. Breaking the silence. Aust Fam Physician 1998;27:45-7.
17. Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol (R Coll Radiol) 1999;11:46-8.
18. Jeffries SA, Robinson JW, Craighead PS, Keats MR. An effective group psychoeducational intervention for improving compliance with vaginal dilation: A randomized controlled trial. Int J Radiat Oncol Biol Phys 2006;65:404-11.
19. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early stage ovarian cancer survivors. Int J Gynecol Cancer 2008;18:1183-93.
20. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol 2008;108:348-54.
21. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004;22:881-9.
22. Stratton P, Turner ML, Childs R, Barrett J, Bishop M, Wayne AS, Pavletic S. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007;110:1041-9.
23. Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility and menopause related treatment effects among women who undergo hematopoietic stem cell transplantation: Changes in perceived importance over time. Biol Blood Marrow Transplant 2009;15:1465-74.
24. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-7, 14.
25. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. Sexual dysfunction after premenopausal stage I and II breast cancer: Do androgens play a role? J Sex Med 2008;5:1898-906.
26. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261-71.
27. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14(1 suppl):S20-S40.
28. Kehoe SM, Kauff ND. Screening and prevention of hereditary gynecologic cancers. Semin Oncol 2007;34:406-10.
29. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophprectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
30. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 2001;1:149-56.
31. Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003;89:281-7.
32. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-8.
33. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy verses gynecologic screening for ovarian cancer. Gynecol Oncol 2009;112:594-600.
34. Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, Brzezinski A. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 2009;12:404-9.
35. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576-82.
36. Van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study. J Clin Oncol 2003;21:3867-74.
37. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: Reproductive and late effects of treatment. J Clin Oncol 2003;21:4184-93.
38. Carter J, Rowland K, Chi DS, Brown C, Abu-Rustum N, Castiel M, Barakat RR. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol 2005;97:90-5.
39. Wenzel L, Dogan-Ates A, Habbal R, Berkowitz R, Goldstein DP, Bernstein M, Kluhsman BC, Osann K, Newlands E, Seckl MJ, Hancock B, Cella D. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr 2005;34:94-8.
40. Sadovsky R, Basson R, Krychman M, Morales AM, Schover L, Wang R, Incrocci L. Cancer and sexual problems. J Sex Med 2010;7:349-73.
41. Carter J, Raviv L, Applegarth L, Ford JS, Josephs L, Grill E, Sklar C, Sonoda Y, Baser RE, Barakat RR. A cross-sectional study of the psychosexual impact of cancer-related infertility in women: Third-party reproductive assistance. J Cancer Surviv 2010; [Epub ahead of print].
42. Cella D, Fallowfield LJ. Recognition and management of treatment related side-effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167-80.
43. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-64.
44. Schover LR, Jenkins R, Sui D, Adams JH, Marion MS, Jackson KE. Randomized trial of peer counseling on reproductive health in African American breast cancer survivors. J Clin Oncol 2006;24:1620-6.
45. Joffe H, Soares CN, Thurston RC, White DP, Cohen LS, Hall JE. Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakening, in women with vasomotor symptoms. Menopause 2009;16:1-9.
46. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in U.S. population-based study shows negative impact on health-related quality of life. Maturitas 2009;62:153-9.
47. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
48. van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerized cytometry. J Clin Pathol 2002;55:446-51.
49. Wu JP, Fielding SL, Fiscella K. The effect of polycarbophil gel (Replens) on bacterial vaginosis: A pilot study. Eur J Obstet Gynecol Reprod Biol 2007;30:132-4.
50. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63.
51. Loprinzi CL, Abu-Ghazaieh S, Sloan JA, vanHaelst-Pisani C, Hammer AH, Rowand KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73.
52. Caswell M, Kane M. Comparison of the moisturization efficacy of two vaginal moisturizers: Pectin versus polycarbophil technologies. J Cosmet Sci 2002;53:81-7.
53. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: An open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 2008;12:411-6.
54. Ekin M, Yasar L, Savan K, Temur M, Uhri M, Gencer I, Ki{dotless}vanç E. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet 2010; [Epub ahead of print].
55. Rosenbaum TY. Pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: A literature review. J Sex Med 2007;4:4-13.
56. Goldfinger C, Pukall CF, Gentilcore-Saulnier E, McLean L, Chamberlain S. A prospective study of pelvic floor physical therapy: Pain and psychosexual outcomes in provoked vestibulodynia. J Sex Med 2009;6:1955-68.
57. Tu FF, Holt J, Gonzales J, Fitzgerald CM. Physical therapy evaluation of patients with chronic pelvic pain: A controlled study. Am J Obstet Gynecol 2008;198:272.e1-7.
58. Lowenstein L, Gruenwald I, Gartman I, Vardi Y. Can stronger pelvic muscle floor improve sexual function? Int Urogynecol J Pelvic Floor Dysfunct 2010;21:553-6.
59. Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small W Jr, Mundt AJ. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 2005;61:1078-86.
60. Billups KL, Berman L, Berman J, Metz ME, Glennon ME, Goldstein I. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001;27:435-41.
61. Schover LR. Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program 2005;523-7.
62. Schover LR. Sexuality and fertility after cancer. Hoboken, NJ: John Wiley & Sons; 1997:116-31.
63. Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003;(1):CD003750.
64. Lutfey KE, Link CL, Rosen RC, Wiegel M, McKinlay JB. Prevalence and correlates of sexual activity and function in women: Results from the Boston Area Community Health (BACH) Survey. Arch Sex Behav 2009;38:514-27.
65. Addis IB, van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH. Reproductive risk factors for incontinence study at Kaiser Study Group. Sexual activity and function in middle-aged and older women. Obstet Gynecol 2006;107:755-64.
66. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500.
67. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-6.
68. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
69. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
70. Jick SS, Hagberg KW, Kaye JA, Jick H. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 2009;113:74-80.
71. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: A systematic review and meta-analysis. Menopause 2005;12:668-78.
72. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-60.
73. Ganz PA, Greendale GA, Kahn B, O'Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer 1999;86:814-20.
74. Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, Sismondi P. Menopause after breast cancer: A survey on breast cancer survivors. Maturitas 2003;45:29-38.
75. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357-69.
76. Panjari M, Davis SR. DHEA for postmenopausal women: A review of the evidence. Maturitas 2010;66:172-9.
77. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Mayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897-906.
78. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907-22.
79. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-31.
80. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010;17:242-55.
81. Hordern AJ, Street AF. Communicating about patient sexuality and intimacy after cancer: Mismatched expectations and unmet needs. Med J Aust 2007;186:224-7.
82. Berman L, Berman J, Felder S, Pollets D, Chhabra S, Miles M, Miles M, Powell JA. Seeking help for sexual function complaints: What gynecologists need to know about the female patient's experience. Fertil Steril 2003;79:572-6.
83. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt) 2009;18:461-8.
84. Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003;88:666-71.
85. Wiggins DL, Wood R, Granai CO, Dizon DS. Sex, intimacy, and the gynecologic oncologists: Survey results of the New England Association of Gynecologic Oncologists (NEAGO). J Psychosoc Oncol 2007;25:61-70.
86. Brotto LA, Heiman JR, Goff B, Greer B, Lentz GM, Swisher E, Tamimi H, Van Blaricom A. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch Sex Behav 2008;37:317-29.
87. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6:1549-60.